Loading clinical trials...
Loading clinical trials...
A Phase I Study of OTS167PO, a MELK Inhibitor, to Evaluate Safety, Tolerability and Pharmacokinetics in Patients With Advanced Breast Cancer and Dose-Expansion Study in Patients With Triple Negative Breast Cancer
Conditions
Interventions
OTS167PO
Locations
8
United States
Norwalk Hospital
Norwalk, Connecticut, United States
Emory University, Winship Cancer Institute
Atlanta, Georgia, United States
Kapi'olani Medical Center for Women & Children
Honolulu, Hawaii, United States
Dartmouth Cancer Center/Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States
Weill Cornell Medicine | NewYork-Presbyterian
New York, New York, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Start Date
May 29, 2017
Primary Completion Date
September 1, 2027
Completion Date
September 1, 2027
Last Updated
February 25, 2026
Lead Sponsor
OncoTherapy Science, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions